EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and Evaluation of Next-Gen Inhibitors Targeting SARS-CoV-2 3CL Protease Clinical Variants

Sydney N Bogan iD, Misa S Meadows iD, Uttara Jayashankar, Nidhi Walia, Iddum Satyanarayana, Ashish Sharma iD, Somayeh Ghazi, Monika Yadav, Arun K Ghosh iD, Andrew D Mesecar iD

ACS Infectious Diseases · 13.11.2026 · 12 (11) · 3835-3847

DOI: 10.1021/acsinfecdis.6c00789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 28.10.2026. Verfasst von Sydney N Bogan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Agriculture, Purdue University, West Lafayette, Indiana47907, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH Office of the Director, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 3C-like protease (3CLpro), also known as main protease (Mpro), is currently the target of the commercially available drugs nirmatrelvir and simnotrelvir which are used to treat SARS-CoV-2 infections. Global sequencing efforts of clinical isolates of SARS-CoV-2 from infected patients treated with nirmatrelvir have identified several 3CLpro clinical variants that are potentially drug resistant. Two variants, E166 and S144, have been widely studied and confirmed to have drug resistance in vitro. Using the Coronavirus 3D database, we identified and characterized ten additional SARS-CoV-2 3CLpro clinical variants deemed likely to render drug resistance. Of these, we identified a new variant, V186G, as being highly drug resistant, i.e., 116-times, 44-times, and 25-times more resistant to nirmatrelvir, simnotrelvir, and the inhibitor GRL-051-22, respectively, than the wild type. The V186G variant also displayed a 23-fold decrease in dimerization affinity. Surprisingly, no changes in drug resistance or dimerization affinity were observed for the V186F or V186I variants. X-ray structures of WT, V186G, V186F, M165I, M49I, and T190I in complex with the inhibitor GRL-051-22 were determined at resolutions between 1.3 Å and 1.9 Å revealing only small structural changes associated with any of the variants, e.g., <1.5 Å in the S2 loop of the V186G variant. Structure-based design was then used to overcome SARS-CoV-2 V186G 3CLpro drug resistance, producing the compound GRL-157-23 which is 6.5-times more potent against the V186G variant compared with the wild type. Structure–activity data for six designed compounds and their interactions with the ten variants revealed an important crosstalk between the SARS-CoV-2 3CLpro S2 and S4 subsites that plays a key role in the kinetic activity and inhibition of these variants. These results demonstrate that it is possible to design and optimize drug scaffolds that target 3CLpro variants to overcome potential drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsCOVID-19 Drug TreatmentProtease InhibitorsHumansDrug DesignDrug Resistance, ViralPyrrolidinonesAzabicyclo Compounds

Stichwörter der Autor:innen

3CLproSARS-CoV-2clinical variantsdrug discoverydrug resistancenext-gen inhibitorsnirmatrelvir

Substanzen

Coronavirus 3C ProteasesAntiviral AgentsProtease Inhibitors3C-like proteinase, SARS-CoV-2nirmatrelvirPyrrolidinonesAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Biochemistry, College of Agriculture, Purdue University, West Lafayette, Indiana47907, United States.
  • Department of Biological Sciences, College of Science, Purdue University, West Lafayette, Indiana47907, United States.
  • Department of Chemistry, College of Science, Purdue University, West Lafayette, Indiana47907, United States.
  • Department of Medicinal Chemistry and Molecular Pharmacology, College of Science, Purdue University, West Lafayette, Indiana47907, United States.

ORCID-Profile: Sydney N Bogan, Misa S Meadows, Ashish Sharma, Arun K Ghosh, Andrew D Mesecar

Förderung

  • NIH Office of the Director
  • NIGMS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Argonne National Laboratory
  • National Institute of General Medical Sciences

Zitieren

APA

Bogan, S. N., Meadows, M. S., Jayashankar, U., Walia, N., Satyanarayana, I., Sharma, A., Ghazi, S., Yadav, M., Ghosh, A. K., & Mesecar, A. D. (2026). Design and Evaluation of Next-Gen Inhibitors Targeting SARS-CoV-2 3CL Protease Clinical Variants. ACS Infectious Diseases, 12(11), 3835-3847. https://doi.org/10.1021/acsinfecdis.6c00789

Vancouver

Bogan SN, Meadows MS, Jayashankar U, Walia N, Satyanarayana I, Sharma A, et al. Design and Evaluation of Next-Gen Inhibitors Targeting SARS-CoV-2 3CL Protease Clinical Variants. ACS Infectious Diseases. 2026;12(11):3835-3847. doi:10.1021/acsinfecdis.6c00789

BibTeX
@article{Bogan2026,
  author = {Bogan, Sydney N and Meadows, Misa S and Jayashankar, Uttara and Walia, Nidhi and Satyanarayana, Iddum and Sharma, Ashish and Ghazi, Somayeh and Yadav, Monika and Ghosh, Arun K and Mesecar, Andrew D},
  title = {Design and Evaluation of Next-Gen Inhibitors Targeting SARS-CoV-2 3CL Protease Clinical Variants},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {11},
  pages = {3835--3847},
  doi = {10.1021/acsinfecdis.6c00789}
}
Kostenlos starten →